Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety
- 14 February 2002
- Vol. 40 (7) , 923-928
- https://doi.org/10.1016/s0041-0101(02)00086-7
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in miceToxicon, 2001
- Preclinical update on BOTOX® (botulinum toxin type A)‐purified neurotoxin complex relative to other botulinurn neurotoxin preparationsEuropean Journal of Neurology, 1999
- Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A–responsive cervical dystoniaNeurology, 1999
- Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humansNeuroscience Letters, 1998
- Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type AJournal of Neurology, Neurosurgery & Psychiatry, 1998
- Botulinum Neurotoxin C1 Cleaves both Syntaxin and SNAP-25 in Intact and Permeabilized Chromaffin Cells: Correlation with Its Blockade of Catecholamine ReleaseBiochemistry, 1996
- Response and immunoresistance to botulinum toxin injectionsNeurology, 1995
- Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin.The EMBO Journal, 1993
- Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves.The Journal of cell biology, 1986
- The action of botulinum toxin on the neuro‐muscular junctionThe Journal of Physiology, 1949